US HB2369 | 2023-2024 | 118th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on March 29 2023 - 25% progression
Action: 2023-04-07 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on March 29 2023 - 25% progression
Action: 2023-04-07 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To amend the Federal Food, Drug, and Cosmetic Act with respect to in vitro clinical tests, and for other purposes.
Title
VALID Act of 2023 Verifying Accurate Leading-edge IVCT Development Act of 2023
Sponsors
Rep. Larry Bucshon [R-IN] | Rep. Diana DeGette [D-CO] | Rep. Thomas Kean [R-NJ] | Rep. Anna Eshoo [D-CA] |
History
Date | Chamber | Action |
---|---|---|
2023-04-07 | House | Referred to the Subcommittee on Health. |
2023-03-29 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2023-03-29 | House | Introduced in House |
Subjects
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/118th-congress/house-bill/2369/all-info |
Text | https://www.congress.gov/118/bills/hr2369/BILLS-118hr2369ih.pdf |